HaploX Stock

haplox.cnHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $42.87MM

HaploX aims to integrate liquid biopsy technology, gene sequencing, artificial intelligence, big data, and other technologies to improve the management of cancer patients.

Register for Details

For more details on financing and valuation for HaploX, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for HaploX.

Register Today

Team

Management Team

Wen Yuan
Chief Financial Officer & Co-Founder
Fang Wen
Chief Operating Officer & Co-Founder
Chen Shifu Ph.D
Chief Technology Officer & Co-Founder
Yan Ming Xu Ph.D
Co-Founder, Chief Executive Officer & Chairman

Board Members

Yan Ming Xu Ph.D

Other companies like HaploX in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

VCs invest $32m in China's HaploX Biotechnology | AVCJ
A group of investors including SBCVC and Kexin Capital have backed a $32 million funding round for China’s HaploX Biotechnology. ,Greater China,Healthcare,Technology,Early-stage ,China,Softbank China Venture Capital,Venture
Updated on: Sep 29, 2023